{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-006139","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.169724+00:00","generated_at":"2026-06-18T12:25:39.692660+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Heron launches APONVIE IV for PONV prevention; cites 50% fewer vomiting vs ondansetron","bullets":["APONVIE (aprepitant injectable emulsion) is first IV NK1 receptor antagonist for postoperative nausea and vomiting (PONV).","Single IV push achieves ≥97% brain receptor occupancy within 5 minutes and maintains therapeutic levels for 48 hours.","Aprepitant reduced vomiting by ~50% in first 24 and 48 hours vs IV ondansetron in clinical trials.","Target market: ~36 million U.S. procedures annually in high/moderate PONV risk patients; CEO sees potential for several hundred million dollars in sales.","Launch leverages existing acute-care commercial team with no additional field force or significant external spend."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-006139","json":"https://secwatch.observer/filing/0000950170-23-006139.json","markdown":"https://secwatch.observer/filing/0000950170-23-006139.md","text":"https://secwatch.observer/filing/0000950170-23-006139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017023006139/0000950170-23-006139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017023006139/hrtx-20230306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T12:25:39.692660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}